SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Phaarmasia - Quaterly Results

09 Nov 2021 Evaluate
The company witnessed a 18.50% growth in the revenue at Rs. 52.90 millions for the quarter ended September 2021 as compared to Rs. 44.64 millions during the year-ago period.The Net Loss for the quarter ended September 2021 is Rs. -7.10 millions as compared to Net Profit of Rs. 0.83 millions of corresponding quarter ended September 2020Operating profit Margin for the quarter ended September 2021 slipped to -6.48% as compared to 1.92% of corresponding quarter ended September 2020


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 52.90 44.64 18.50 91.80 97.15 -5.51 198.95 244.54 -18.64
Other Income 1.59 0.83 91.57 2.34 1.54 51.95 8.94 5.78 54.67
PBIDT -6.48 1.92 -437.50 -5.20 3.52 -247.73 8.32 13.97 -40.44
Interest 0.01 0.03 -66.67 0.02 0.05 -60.00 0.12 0.37 -67.57
PBDT -6.49 1.89 -443.39 -5.22 3.47 -250.43 8.20 13.60 -39.71
Depreciation 0.74 0.86 -13.95 1.47 1.71 -14.04 3.42 3.99 -14.29
PBT -7.23 1.03 -801.94 -6.69 1.76 -480.11 4.78 9.61 -50.26
TAX -0.13 0.20 -165.00 0.00 0.39 -100.00 1.67 4.21 -60.33
Deferred Tax 0.04 -0.05 -180.00 0.00 -0.09 -100.00 -0.18 1.55 -111.61
PAT -7.10 0.83 -955.42 -6.69 1.37 -588.32 3.11 5.40 -42.41
Equity 68.27 68.27 0.00 68.27 68.27 0.00 68.27 68.27 0.00
PBIDTM(%) -12.25 4.30 -384.80 -5.66 3.62 -256.34 4.18 5.71 -26.80

Phaarmasia Share Price

113.80 1.80 (1.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×